Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia

Haemophilia

Volumn 17, Issue 1, 2011, Pages 103-111

  Ragni, M V ^a,b   Moore, C G ^a   Soadwa, K ^a   Nalesnik, M A ^a   Zajko, A B ^c   Cortese Hassett, A ^a,c   Whiteside, T L ^d   Hart, S ^c   Zeevi, A ^a   Li, J ^a   Shaikh, O S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Hemophilia Center of Western Pennsylvania   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Fibrosis; Haemophilia; Hepatitis C; Metavir; Receiver operating curve; Transfusion

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CYTOKINE; FERRITIN; HEPATITIS C ANTIBODY;

ADULT; ARTICLE; CROSSOVER PROCEDURE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 79951904579     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02366.x     Document Type: Article

References (40)

1. Ragni MV, Winkelstein A, Kingsley LA, Spero A, Lewis JH. 1986 Update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in hemophiliacs. Blood 1987; 70: 786-90.
2. Spero JA, Lewis J, van Thiel DH, Hasiba U, Rabin BS. Asymptomatic structural liver disease in hemophilia. N Engl J Med 1978; 298: 1373-8.
3. Seeff LB, Hollinger FB, Alter HJ et al. Long term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-63.
4. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-51.
5. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C. J Infect Dis 2001; 183: 1112-5.
6. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection. N Engl J Med 1996; 328: 327-35.
7. Kekow J, Wachsman W, McCutchan JA et al. Transforming growth factor-β and suppression of humoral immune responses in HIV infection. J Clin Invest 1991; 87: 1010-6.
8. Matsumoto K, Fuhi H, Michalopoulos G, Fung JJ, Demetris AH. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors: Il-6, HGF, and EGF promote DNA synthesis in vitro. Hepatology 1994; 20: 376-82.
9. Palella FJ, Delaney KJ, Moorman AC et al. Declining morbidity among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
10. Ragni MV, Schillo R, Dang Q. HAART improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009; 15: 552-8.
11. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2005; 3: 175-83.
12. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV co-infection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-89.
13. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-20.
14. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26(Suppl 1): S57-61.
15. Little AF, Zajko AB, Orons PD. Transjugular liver biopsy: a prospective study in 43 patients with Quick-Core biopsy needle. J Vasc Interventional Radiol 1996; 7: 127-31.
16. Sterling RK, Lissen E, Clumeck N et al. Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV co-infection. Hepatology 2006; 43: 1317-25.
17. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.
18. Le Calvez S, Thabut D, Messous D et al. The predictive value of fibrotest vs APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004; 39: 862-3.
19. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
20. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to- platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.
21. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C co-infection using a noninvasive marker. J Acquir Immunodef Syndr 2007; 44: 463-9.
22. Schiavon LL, Schiavon JL, Filho RJ et al. Simple blood tests as noninvasive makers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46: 307-14.
23. Maor Y, Cales P, Bashari D et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected hemophilia patients. Haemophilia 2007; 13: 722-9.
24. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
25. Ezure T, Sakamoto T, Tsuji H et al. The development and compensation of biliary cirrhosis in interleukin-6 deficient mice. Am J Pathol 2000; 156: 1627-39.
26. Yokomuro S, Tsuji H, Lunz JG et al. Growth control in human biliary epithelial cells by interleukin-6, hepatocyte growth factor, transforming growth factor β1, and activin A: A comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000; 32: 26-35.
27. Kasper CK, Kipnis SA. Hepatitis and clotting factor concentrates. JAMA 1972; 221: 510.
28. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
29. Ishak K, Baptista A, Bianchi L et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
30. The French Metavir Cooperative study Group. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
31. Whiteside TL. Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol 1994; 14: 3237-9.
32. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS: correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995; 274: 58-65.
33. Girnita DM, Webber SA, Ferrell R et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 2006; 82: 1774-80.
34. Wong VS, Baglin T, Beacham E, Wight DDG, Petrik J, Alexander GJM. The role of liver biopsy in hemophiliacs infected with the hepatitis C virus. Br J Haematol 1997; 97: 343-7.
35. Kelleher TB, Afdahl N. Assessment of liver fibrosis in co-infected patients: prediction of hepatic fibrosis in HIV/HCV co-infected patients. J Hepatol 2006; 44(Suppl): S126-31.
36. Nunes D, Fleming C, Offner G et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immunodef Syndr 2005; 40: 538-44.
37. Ragni MV, DeVera M, Roland M et al. Outcomes in HIV/HCV Hemophilic vs. non- Hemophilic Transplant Candidates: The HIV-TR Study. San Francisco CA: 17th Annual Conference on Retroviruses and Opportunistic Infections, Q-1006, Feb 18 (Late Breaker abstract), 2010.
38. Ragni MV, Sherman KE, Jordan JA. Viral pathogens. State of the Art:XXIX International Congress of the World Federation of Hemophilia. Haemophilia 2010; 16: 40-6.
39. Subramanian A, Sulkowski M, Barin B et al. MELD is an important predictor of pre-transplant mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138: 159-64.
40. Molleken C, Sitek B, Henkel C et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009; 49: 1257-66.